Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Why Hims & Hers Health Stock Sank This Week
Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast revenue ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Nasdaq5d
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.
AOL18d
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales ...
Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
Nasdaq24d
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 156. ...